NovoCure Limited (NVCR)
| Market Cap | 2.04B +1.7% |
| Revenue (ttm) | 674.41M +8.5% |
| Net Income | -173.05M |
| EPS | -1.54 |
| Shares Out | 115.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,408,655 |
| Open | 17.82 |
| Previous Close | 18.05 |
| Day's Range | 17.44 - 18.25 |
| 52-Week Range | 9.82 - 20.06 |
| Beta | 0.90 |
| Analysts | Buy |
| Price Target | 27.29 (+55.23%) |
| Earnings Date | Apr 30, 2026 |
About NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Lim... [Read more]
Financial Performance
In 2025, NovoCure's revenue was $655.35 million, an increase of 8.28% compared to the previous year's $605.22 million. Losses were -$136.23 million, -19.21% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price target is $27.29, which is an increase of 55.23% from the latest price.
News
Novocure price target raised to $17 from $13.50 at Wells Fargo
Wells Fargo raised the firm’s price target on Novocure (NVCR) to $17 from $13.50 and keeps an Equal Weight rating on the shares. The firm notes Q1 results were ahead…
Novocure price target raised to $20 from $16 at Evercore ISI
Evercore ISI raised the firm’s price target on Novocure (NVCR) to $20 from $16 and keeps an Outperform rating on the shares.
Novocure reports Q1 EPS (62c), consensus (51c)
Reports 1Q revenue $174.055M, consensus $167.77M. “This was a very strong start to the year for Novocure (NVCR) and we are pleased with the progress made across our commercial and…
Novocure raises FY26 revenue view to $690M-$710M from $675M-$705M
Consensus $694.68M
NovoCure Earnings Call Transcript: Q1 2026
Double-digit growth in active patients and net revenue marked a strong Q1 2026, driven by the successful U.S. launch of Optune Pax for pancreatic cancer and continued momentum in GBM and international markets. Updated guidance reflects confidence in sustained growth and progress toward profitability.
Novocure Reports First Quarter 2026 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026. Novocure is a global oncology company working to extend su...
Novocure price target lowered to $16 from $23 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Novocure (NVCR) to $16 from $23 and keeps an Outperform rating on the shares as part of the firm’s…
Novocure to Report First Quarter 2026 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will...
Novocure announces results from Phase 2 PANOVA-4 trial met primary endpoint
Novocure (NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields, TTFields, therapy concomitant with atezolizumab, gemcitabine and nab-paclitaxel as a first-li...
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (...
NovoCure Transcript: Leerink Global Healthcare Conference 2026
Leadership is driving a shift toward commercially viable indications, focusing on glioblastoma and pancreatic cancer, with disciplined clinical and commercial strategies. Growth is expected from deeper market penetration, new trial data, and leveraging a multi-indication field force.
Novocure gets reimbursement approval in Japan for Optune Lua
Novocure (NVCR) announced that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua through the country’s National Health Insurance coverage. Optune Lua is approved in ...
Novocure gets reimbursement approval in Japan for Optune Lua
Novocure (NVCR) announced that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua through the country’s National Health Insurance coverage. Optune Lua is approved in ...
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country's National He...
Novocure to Participate in 2026 Leerink Global Healthcare Conference
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 2026 Leerink Global Healthcare Conference.
NovoCure Earnings Call Transcript: Q4 2025
Record 2025 revenue was driven by international growth and new product launches, with FDA approval for Optune Pax and guidance for continued expansion in 2026. Profitability is a key focus, with adjusted EBITDA targeted to reach break even this year.
Novocure reports Q4 EPS (22c), consensus (41c)
Reports Q4 revenue $174.35M, consensus $173.36M. “In 2025, a record number of patients received treatment with Novocure’s (NVCR) Tumor Treating Fields therapy, a milestone that reflects our growth and...
Novocure sees FY26 revenue $675M-$705M, consensus $681.24M
Sees FY26 adjusted EBITDA loss of $20M to flat. The company said, “This guidance assumes full-year low-to-mid single digit net revenue growth from Optune Gio, net revenue contribution from Optune…
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update.
Novocure says CMS rescinds revocation of billing privileges
Novocure (NVCR) disclosed that on February 24, it received a letter from Centers for Medicare and Medicaid Services rescinding the revocation of billing privileges and stating the company’s Medicare b...
Novocure jumps 11% after CMS reinstates Medicare billing privileges
08:53 EST Novocure (NVCR) jumps 11% after CMS reinstates Medicare billing privileges
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the province of British Columbia, Canada, will now cover Tumor Treating Fields (TTFields) therapy for the treatment of ...
Unusually active option classes on open February 12th
Unusual total active option classes on open include: NovoCure (NVCR), Teucrium Soybean (SOYB), BP (BP), Super Group Limited (SGHC), Crocs (CROX), Fedex (FDX), Direxion Daily Small Cap Bear 3X Shares…
Why Is NovoCure Stock (NVCR) Up Today?
NovoCure stock underwent a massive rally after it received approval from the FDA for its pancreatic cancer treatment.
This Biotech Stock Is Jumping 25% After Getting an FDA Boost
Novocure stock surged after the Food and Drug Administration approved its Optune Pax product, which delivers tumor treating fields, for certain pancreatic cancers.